1.Plasmodium vivax dhfr Mutations among Isolates from Malarious Areas of Iran.
Jalal ZAMAN ; Abbas SHAHBAZI ; Mohammad ASGHARZADEH
The Korean Journal of Parasitology 2011;49(2):125-131
The use of sulfadoxine and pyrimethamine (SP) for treatment of vivax malaria is uncommon in most malarious areas, but Plasmodium vivax isolates are exposed to SP because of mixed infections with other Plasmodium species. As P. vivax is the most prevalent species of human malaria parasites in Iran, monitoring of resistance of the parasite against the drug is necessary. In the present study, 50 blood samples of symptomatic patients were collected from 4 separated geographical regions of south-east Iran. Point mutations at residues 57, 58, 61, and 117 were detected by the PCR-RFLP method. Polymorphism at positions 58R, 117N, and 117T of P. vivax dihydrofolate reductase (Pvdhfr) gene has been found in 12%, 34%, and 2% of isolates, respectively. Mutation at residues F57 and T61 was not detected. Five distinct haplotypes of the Pvdhfr gene were demonstrated. The 2 most prevalent haplotypes were F57S58T61S117 (62%) and F57S58T61N117 (24%). Haplotypes with 3 and 4 point mutations were not found. The present study suggested that P. vivax in Iran is under the pressure of SP and the sensitivity level of the parasite to SP is diminishing and this fact must be considered in development of malaria control programs.
Amino Acid Substitution/genetics
;
Antimalarials/*pharmacology
;
Drug Combinations
;
*Drug Resistance
;
Haplotypes
;
Humans
;
Iran
;
Malaria, Vivax/*parasitology
;
*Mutation, Missense
;
Plasmodium vivax/*enzymology/genetics/isolation & purification
;
Polymorphism, Genetic
;
Pyrimethamine/*pharmacology
;
Sulfadoxine/*pharmacology
;
Tetrahydrofolate Dehydrogenase/*genetics
2.Pulmonary Tuberculosis Diagnosis: Where We Are?.
Hamed Ebrahimzadeh LEYLABADLO ; Hossein Samadi KAFIL ; Mehdi YOUSEFI ; Mohammad AGHAZADEH ; Mohammad ASGHARZADEH
Tuberculosis and Respiratory Diseases 2016;79(3):134-142
In recent years, in spite of medical advancement, tuberculosis (TB) remains a worldwide health problem. Although many laboratory methods have been developed to expedite the diagnosis of TB, delays in diagnosis remain a major problem in the clinical practice. Because of the slow growth rate of the causative agent Mycobacterium tuberculosis, isolation, identification, and drug susceptibility testing of this organism and other clinically important mycobacteria can take several weeks or longer. During the past several years, many methods have been developed for direct detection, species identification, and drug susceptibility testing of TB. A good understanding of the effectiveness and practical limitations of these methods is important to improve diagnosis. This review summarizes the currently-used advances in nonmolecular and molecular diagnostics.
Diagnosis*
;
Mycobacterium tuberculosis
;
Pathology, Molecular
;
Tuberculosis
;
Tuberculosis, Multidrug-Resistant
;
Tuberculosis, Pulmonary*
3.False-Positive Mycobacterium tuberculosis Detection: Ways to Prevent Cross- Contamination
Mohammad ASGHARZADEH ; Mahdi Asghari OZMA ; Jalil RASHEDI ; Mahdavi POOR ; Vahid AGHARZADEH ; Ali VEGARI ; Behrooz SHOKOUHI ; Khudaverdi GANBAROV ; Nima Najafi GHALEHLOU ; Hamed Ebrahmzadeh LEYLABADLO ; Hossein Samadi KAFIL
Tuberculosis and Respiratory Diseases 2020;83(3):211-217
The gold standard method for diagnosis of tuberculosis is the isolation of Mycobacterium tuberculosis through culture, but there is a probability of cross-contamination in simultaneous cultures of samples causing false-positives. This can result in delayed treatment of the underlying disease and drug side effects. In this paper, we reviewed studies on falsepositive cultures of M. tuberculosis . Rate of occurrence, effective factors, and extent of false-positives were analyzed. Ways to identify and reduce the false-positives and management of them are critical for all laboratories. In most cases, falsepositive is occurring in cases with only one positive culture but negative direct smear. The three most crucial factors in this regard are inappropriate technician function, contamination of reagents, and aerosol production. Thus, to reduce false-positives, good laboratory practice, as well as use of whole-genome sequencing or genotyping of all positive culture samples with a robust, extra pure method and rapid response, are essential for minimizing the rate of false-positives. Indeed, molecular approaches and epidemiological surveillance can provide a valuable tool besides culture to identify possible false positives.